Smoking addicts may be able to inject themselves in a few years with a vaccine to help fight their nicotine habit, following a deal between GlaxoSmithKline and biotech company Nabi Pharmaceuticals sealed yesterday.
GSK will pay $40m (€26.7m) up front and as much as $500m in the future to Nabi, which is based in Rockville, Maryland, as it tries to develop and launch the world's first anti-smoking vaccine.
